Immunosuppressive treatment has shown to be effective in various ocular inflammatory disorders. Factors limiting their use are the individual response and the rate of side effects. This report summarizes our knowledge about the use of mycophenolate mofetil (MMF) in the treatment of ocular cicatricial pemphigoid (OCP), uveitis, atopic keratoconjunctivitis (AKC), prevention of graft rejection after penetrating keratoplasty (PK) and scleritis. Controlled studies have been performed for prevention of graft rejection after PK, showing MMF as effective in the prevention of graft rejection as cyclosporine A. In experimental uveitis, MMF has been demonstrated to be highly effective in prevention of retinal destruction. A number of studies have now shown that MMF also seems effective in uveitis. There are also studies with smaller patient groups which point out the effectiveness of MMF in OCP, AKC, and scleritis. In most of the studies, the spectrum of side effects was small, compared to other immunosuppressives.
KumariS, BholKC, SimmonsRKIdentification of ocular cicatricial pemphigoid antibody binding site(s) in human b4 integrin. Invest Ophthalmol Vis Sci2001; 42: 379–385.
KreutzerB, StübigerN, ThielHJ, ZierhutM.Oculomucocutaneous changes as paraneoplastic syndromes. German J Ophthalmol1996; 5: 176–181.
4.
FosterCS.Cicactricial pemphigoid. Trans Am Ophthalmol Soc1986; 84: 527–663.
5.
NeumannR, TauberJ, FosterCS.Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology1991; 98: 858–862.
6.
ZurdelJ, AboalchamatB, ZierhutM, StübigerN, BialasiewiczA, EngelmannK.Erste klinische Erfahrung mit Mycophenolatmofetil bei der immunsuppressiven Therapie des okulären Pemphigoides. Klin Monatsbl Augenheilk2001; 218: 222–228.
7.
ReisA, ReinhardT, SundmacherR, AlthausC, VoiculescuA, KutkuhnB.Mycophenolate mofetil in ocular immunological disorders. A survey of the literature and 3 case reports. Klin Monatsbl Augenheilk1998; 213: 257–261.
8.
ChanaudNP, VisticaBP, EuguiE, NussenblattRB, AllisonAC, GeryI.Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Exp Eye Res1995; 61: 429–434.
9.
GeryI, MochizukiM, NussenblattRB.Retinal specific antigens and immunopathogenic processes they provoke. Prog Retinal Res1986; 5: 75.
10.
CaspiRR, RobergeFG, ChanCCExperimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol1988; 140: 1490–1495.
11.
LarkinG, LightmanS.Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology1999; 218: 222–228.
12.
ZierhutM, StübigerN, AboalchamatW, LandenbergerH, BialasiewiczAA, EngelmannK.Immunsuppressive Therapie mit Mycophenolat Mofetil (CellCept) in der Behandlung der Uveitis. Ophthalmologe2001; 98: 647–651.
13.
LauCH, ComerM, LightmanS.Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Exp Ophthal2003; 31: 487–491.
14.
GreinerK, VarikkaraM, SantiagoC, ForresterJV.Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis. Ophthalmologe2002; 99: 691–694.
15.
UchioE, MiyakawaK, IkezawaZ, OhnoS.Systemic and local immunological features of atopic dermatitis patients with ocular complications. Br J Ophthalmol1998; 82: 82–87.
16.
GarrityJA, LiesegangTJ.Ocular complications of atopic dermatitis. Can J Ophthalmol1984; 19: 21–24.
LearJT, EnglishJS, JonesP, SmithAG.Retrospective review of the use of azathioprine in severe atopic dermatitis. J Am Acad Dermatol1996; 35: 642–643.
19.
Hoang-XuanT, PrisantO, HannoucheD, RobinH.Sytemic cyclosporine A in severe atopic keratoconjunctivitis. Ophthalmology1997; 104: 1300–1305.
20.
NeuberK, SchwartzI, ItschertG, DieckAT.Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol2000; 143: 385–391.
21.
ReinhardT, ReisA, BöhringerDSystemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years’ results of a randomized prospective clinical trial. Graefe's Arch Clin Exp Ophthalmol2001; 239: 367–372.
22.
MayerK, ReinhardT, ReisA, VoiculescuA, SundmacherR.Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study. Graefe's Arch Clin Exp Ophthalmol2003; 241: 1051–1054.
23.
NeytsJ, AndreiG, De ClercqE.The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir and penciclovir in vitro and in vivo. Antimicrob Agents Chemother1998; 42: 216–222.
24.
LauCH, Comer, LightmanS.Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol2003; 31: 487–491.
25.
LarkinG, LightmanS.Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Opthalmology1999; 106: 370–374.
